Disease · MONDO_0005369

carcinoid tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinoid tumor. Diseases, record MONDO_0005369. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005369

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinoid tumor; Open Targets
Open Targets ID: MONDO_0005369; Open Targets
Other names: NET G1, carcinoid, carcinoid tumor (disease), carcinoid tumour (disease), neuroendocrine neoplasm G1, neuroendocrine tumor G1, neuroendocrine tumour G1; Open Targets
MeSH: D002276; MeSH
NCI Thesaurus: C2915; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 26 drugs, from DailyMed and EMA Human Drugs; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	EMA Human Drugs, at withdrawal	4	3	2	Drugs and targets
OCTREOTIDE ACETATE	CHEMBL1200480	Protein	Approval	DailyMed	3	1	1	Drugs and targets
TELOTRISTAT ETHYL	CHEMBL2105695	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PAZOPANIB HYDROCHLORIDE	CHEMBL1201733	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
2-METHOXYESTRADIOL	CHEMBL299613	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets67

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
SSTR1	Somatostatin receptor	4	Somatostatin receptor 1 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent	Approval	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	4	Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent	Approval	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	4	Somatostatin receptor 3 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent	Approval	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR5	Somatostatin receptor	4	Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent	Approval	https://conductscience.org/library/genes/6755	Drugs and targets
SSTR4	Somatostatin receptor	3	Somatostatin receptor agonist; Somatostatin receptor binding agent	Approval	https://conductscience.org/library/genes/6754	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	2	Fibroblast growth factor receptor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets

1 to 10 of 67

See all 67 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00412061	Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor	Phase 3	429	2012-03-12	Carcinoid Tumor, Malignant Carcinoid Syndrome	EVEROLIMUS, OCTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT00569127	Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor	Phase 3	427	2016-04-28	Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2	BEVACIZUMAB, OCTREOTIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT03375320	Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors	Phase 3	298	2024-10-16	Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT01841736	Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors	Phase 2	171	2020-06-01	Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1	PAZOPANIB HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01466036	Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors	Phase 2	61	2023-07-20	Carcinoid Tumor, Pancreatic Neuroendocrine Tumor	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT01024387	AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2	60	2017-12-27	Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor	GANITUMAB	Its record names the disease	ClinicalTrials.gov
NCT00454363	Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer	Phase 2	52	2015-04-01	Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor	OCTREOTIDE, PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00088595	Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors	Phase 2	45	2011-05-06	Carcinoid Tumors	PASIREOTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02795858	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors	Phase 2	43	2024-03-05	Carcinoid Tumors	RAMUCIRUMAB	Its record names the disease	ClinicalTrials.gov
NCT00869050	Capecitabine and Temozolomide for Neuroendocrine Cancers	Phase 2	41	2016-06-22	Neuroendocrine Tumors	CAPECITABINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Octreotide, Bevacizumab vs Octreotide, Interferon Alpha-2b: serious adverse events	68 of 197	9 of 194	391	NCT00569127	Trial comparisons
Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: Objective Response Rate (ORR)	3 of 20	7 of 41	61	NCT01466036	Trial comparisons
Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: deaths from any cause	1 of 20	3 of 41	61	NCT01466036	Trial comparisons
Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: serious adverse events	15 of 20	24 of 41	61	NCT01466036	Trial comparisons
Ziv-aflibercept 4mg/kg vs Ziv-aflibercept 2mg/kg: deaths from any cause	1 of 10	0 of 9	19	NCT01782443	Trial comparisons
Ziv-aflibercept 4mg/kg vs Ziv-aflibercept 2mg/kg: serious adverse events	5 of 10	5 of 9	19	NCT01782443	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22778320	RESULT	1	PubMed
41524552	DERIVED	1	PubMed
40902132	DERIVED	1	PubMed
39834129	DERIVED	1	PubMed
39282913	DERIVED	1	PubMed
36395401	DERIVED	1	PubMed
33152282	DERIVED	1	PubMed
28444114	DERIVED	1	PubMed
28384065	DERIVED	1	PubMed
27261467	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005369

GET https://conductscience.org/api/diseases/v1/MONDO_0005369/drugs?page=2

API reference For AI assistants